Results 21 to 30 of about 8,176 (156)
Update on the Role of Rifaximin in Digestive Diseases. [PDF]
, 2023 Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy ...
Moreira, Leticia +22 more
core +1 more source
The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study [PDF]
, 2017 Introduction: Symptomatic uncomplicated diverticular disease of the colon (SUDD) is one of the most common diseases with which patients present to a gastroenterologist. Mild forms of diverticulitis can also be treated using rifaximin. Although numerous
Grażyna Rydzewska, Andrzej Moniuszko
core +1 more source
Rifaximin suspension for the eradication of Helicobacter pylori [PDF]
, 1997 The in vitro sensitivity- of Helicobacter pylori to rifaximin, a new rifamycin antibiotic, was evaluated in 40 clinical isolates by the agar dilution method.
Ferrieri A +24 more
core +1 more source
iMeta, EarlyView.Liver cirrhosis is associated with profound disruption of host–microbiome metabolic interactions. Using paired oral and fecal metagenomics combined with genome‐scale metabolic modeling, we investigated how microbial translocation along the oral–gut axis influences microbial metabolism at different cirrhosis severities.
Yi Jin +21 more
wiley +1 more source
-Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth [PDF]
, 2005 BACKGROUND: Few controlled studies assessing choice and duration of antibiotic therapy for small intestinal bacterial overgrowth are available. AIM: To assess efficacy, safety and tolerability of different doses of rifaximin, a broad spectrum non ...
Lauritano, Ernesto Cristiano +9 more
core
Diverticular Disease and Rifaximin: An Evidence-Based Review [PDF]
, 2023 There have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications.
Martingano, Paola +11 more
core +1 more source
Review of nutrition management of pediatric intestinal pseudo‐obstruction
Nutrition in Clinical Practice, EarlyView.Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman +5 more
wiley +1 more source
Rifaximin to reduce infection in decompensated liver disease [PDF]
, 2022 Background: Bacterial infections remain a significant cause of morbidity and mortality in patients with cirrhosis. Despite, significant improvements in the management of cirrhosis, mortality from infection, particularly secondary infections, remains ...
Nathwani, Rooshi
core +1 more source
Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice [PDF]
, 2023 BACKGROUND: Rifaximin has been increasingly applied in irritable bowel syndrome (IBS) treatment. Whether there were differences in the effects of rifaximin on microbiota from different intestinal segments, especially the small intestine where rifaximin ...
Xiaohua Hou +11 more
core +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.RESTORE is a prospective, double‐blind, placebo‐controlled, crossover trial evaluating Lemborexant in cirrhosis at Cipto Mangunkusumo National Referral Hospital. Both 5 and 10 mg doses reduced PSQI by week 2, with sustained benefits post‐crossover. The 5 mg group improved Stroop Test performance, whereas the 10 mg group had prolonged reaction time ...
Rino Alvani Gani +7 more
wiley +1 more source